Budoneb 0,25 mg/ml & 0,5 mg/ml Film-coated tablets.
PDF Leaflet Revision Date: 13 July 2018
Clinical Summary
Quick overview from the medicine insert
Indication
Management of asthma and acute laryngotracheobronchitis in children.
Dosage (summary)
Adults: 0.5-1 mg twice daily; Children: 0.25-1 mg twice daily based on previous therapy.
Onset of Action / Duration
Onset: 10-30 mins, Duration: 2-3 hours
Special Populations
- Children under 12 months
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety in pregnancy and lactation not established.
Key Drug Interactions
- CYP3A4 inhibitors (e.g., ketoconazole, itraconazole)
Contraindications
- Hypersensitivity to budesonide
- Lung tuberculosis
- Fungal and viral infections
Common side effects
- Oral thrush
- Hoarseness
- Coughing
- Cataract
- Skin bruising
Counselling Points
- Rinse mouth after use
- Wash face after nebuliser use
- Monitor for signs of adrenal insufficiency
Serious warnings
- Not for rapid relief of acute asthma episodes
- Monitor growth in children
- Risk of adrenal insufficiency
Important Disclaimer
The Budoneb 0,25 mg/ml & 0,5 mg/ml Film-coated tablets. professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
